<Summary id="CDR0000799418" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>This evidence-based, expert-reviewed summary discusses the incidence, outcome, clinical presentation, and treatment of pediatric thymoma and thymic carcinoma.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/thymoma/hp/child-thymoma-treatment-pdq">Childhood Thymoma and Thymic Carcinoma (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/thymoma/patient/child-thymoma-treatment-pdq">Childhood Thymoma and Thymic Carcinoma (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038797">thymoma and thymic carcinoma</TermRef></MainTopics><SummaryAbstract><Para id="_1556">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood thymoma and thymic carcinoma. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_1557">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>Pediatric thymic carcinoma</SummaryKeyWord><SummaryKeyWord>Pediatric thymoma</SummaryKeyWord><SummaryKeyWord>Thymic carcinoma</SummaryKeyWord><SummaryKeyWord>Thymoma</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Thymoma and Thymic Carcinoma Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Thymoma and Thymic Carcinoma Treatment</AltTitle><SummarySection id="_2306"><Title>General Information About Childhood Thymoma and Thymic Carcinoma</Title><Para id="_2307">Thymoma and thymic carcinoma originate within the epithelial cells of the thymus, resulting in an anterior mediastinal mass. The term thymoma is customarily used to describe neoplasms that show no overt atypia of the epithelial component.<Reference refidx="1"/> </Para><Para id="_2395">Thymic carcinoma or type C thymoma is a thymic epithelial tumor that exhibits clear-cut cytological atypia and histological features no longer specific to the thymus. Thymic carcinomas have a higher incidence of capsular invasion and metastases.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  </Para><Para id="_2396">Other tumors that
involve the thymus gland include lymphomas, germ cell tumors, carcinomas,
and carcinoids.  Hodgkin lymphoma and non-Hodgkin lymphoma may also
involve the thymus and must be differentiated from true thymomas and thymic carcinomas.</Para><ReferenceSection><Citation idx="1" PMID="16627265">Suster S, Moran CA: Thymoma classification: current status and future trends. Am J Clin Pathol 125 (4): 542-54, 2006.</Citation><Citation idx="2" PMID="21600006">Carretto E, Inserra A, Ferrari A, et al.: Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis 6: 28, 2011.</Citation><Citation idx="3" PMID="22105817">Kelly RJ, Petrini I, Rajan A, et al.: Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29 (36): 4820-7, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_1657"><Title>Childhood Thymoma</Title><SummarySection id="_1658"><Title>Incidence </Title><Para id="_1659">Primary tumors of the thymus are exceptionally rare in children, and very few pediatric studies have been reported.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> A review of the Surveillance, Epidemiology, and End Results (SEER) Program registry from 1973 to 2008 identified 73 cases of malignant anterior mediastinal tumors in patients younger than 20 years.<Reference refidx="2"/> Of these cases, 32% were thymomas, 29% were non-Hodgkin lymphomas, and 22% were Hodgkin lymphomas.  </Para></SummarySection><SummarySection id="_1665"><Title>Clinical Presentation</Title><Para id="_1666"> Childhood thymomas are usually located in the anterior mediastinum and 
discovered during a routine chest x-ray.  Symptoms may include the following:<Reference refidx="3"/></Para><ItemizedList id="_1667" Style="bullet"><ListItem>Cough.</ListItem><ListItem>Difficulty with swallowing.</ListItem><ListItem>Tightness of the chest.</ListItem><ListItem>Chest pain.</ListItem><ListItem>Shortness
of breath.</ListItem><ListItem>Superior vena cava syndrome.</ListItem></ItemizedList><Para id="_2113">About 40% of adults with thymomas have one or more paraneoplastic disorders during their lifetime.<Reference refidx="5"/><Reference refidx="6"/> The most commonly associated disorder is myasthenia gravis, which occurs in approximately 30% of adult patients and has been reported in children.<Reference refidx="5"/> It is important to recognize whether the patient has myasthenia gravis before a thoracotomy of a suspected thymoma. </Para><Para id="_2397">Various other paraneoplastic syndromes have been found to be associated with thymomas. These include pure red cell aplasia, hypogammaglobulinemia, nephrotic syndrome, and autoimmune or immune disorders such as scleroderma, dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and thyroiditis. Endocrine disorders associated with thymomas include hyperthyroidism, Addison disease, and panhypopituitarism.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para></SummarySection><SummarySection id="_2398"><Title>Prognosis</Title><Para id="_1660">The following studies have reported the outcomes of patients with thymomas:</Para><ItemizedList id="_1661" Style="bullet"><ListItem>A review of the SEER Program registry from 1973 to 2008 identified 73 cases of malignant anterior mediastinal tumors in patients younger than 20 years.<Reference refidx="2"/> <ItemizedList id="_2399" Style="bullet"><ListItem>At 10 years, patients with thymomas had worse survival than patients with lymphomas.  </ListItem><ListItem>Patients with thymomas who were treated in an earlier era, from 1973 to 1989, had a 10-year survival rate of 18%. Patients who were treated between 1991 and 2008 had a survival rate of 75%.</ListItem><ListItem>   Presence of metastatic disease and treatment without surgery were associated with a worse outcome.</ListItem></ItemizedList></ListItem><ListItem>A review identified 48 published cases of thymomas in patients younger than 18 years. This review excluded studies of patients with thymic carcinomas.<Reference refidx="3"/><ItemizedList id="_2400" Style="bullet"><ListItem>The review found an association between stage of disease and survival. </ListItem><ListItem>The review also suggested guidelines for treatment.</ListItem><ListItem>The overall 2-year survival rate in this series was 71%.</ListItem></ItemizedList></ListItem><ListItem>The European Cooperative Study Group for Pediatric Rare Tumors identified 16 children with thymomas between 2000 and 2012.<Reference refidx="4"/>  <ItemizedList id="_2401" Style="bullet"><ListItem>Complete resection was achieved in 11 of 16 patients.  </ListItem><ListItem>Fourteen of the 16 patients were alive with no evidence of disease at a median of 5 years from diagnosis.</ListItem></ItemizedList></ListItem></ItemizedList></SummarySection><SummarySection id="_1670"><Title>Treatment of Childhood Thymoma</Title><Para id="_1671">Treatment options for childhood thymoma include the following:</Para><OrderedList id="_2402" Style="Arabic"><ListItem><SummaryRef href="CDR0000799418#_2403" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Surgery</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2405" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2407" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2409" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Octreotide</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2411" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Sunitinib</SummaryRef>.</ListItem></OrderedList><SummarySection id="_2403"><Title>Surgery</Title><Para id="_2404">Surgery is the mainstay of therapy, and an attempt should be made to resect all disease.<Reference refidx="8"/></Para></SummarySection><SummarySection id="_2405"><Title>Radiation therapy</Title><Para id="_2406">Thymoma is relatively radiosensitive, and radiation therapy is used for patients with unresectable or incompletely resected invasive disease.<Reference refidx="7"/> Radiation dosage recommendations are based on the age of the child and the extent of tumor invasion. Total doses of 45 Gy to 50 Gy may be used for control of clear or close margins, 54 Gy for microscopically positive margins, and at least 60 Gy for patients with bulky residual disease.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_2407"><Title>Chemotherapy</Title><Para id="_2408">Chemotherapy is usually reserved
for patients with advanced-stage disease who have not responded to radiation
therapy or corticosteroids.  Agents that have been effective include
doxorubicin, cyclophosphamide, etoposide, cisplatin, ifosfamide, and vincristine.<Reference refidx="1"/><Reference refidx="7"/><Reference refidx="10"/> Responses to regimens containing combinations of some of these agents have ranged from 26% to 100%, and survival rates have been as high as 50%.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></Para></SummarySection><SummarySection id="_2409"><Title>Octreotide</Title><Para id="_2410">Because thymoma shows high uptake of indium In 111–labeled octreotide, trials using this somatostatin analogue have been conducted in patients with refractory disease. In an Eastern Cooperative Oncology Group phase II trial of 42 patients, 4 patients had partial responses to octreotide alone, and 8 patients responded with the addition of prednisone to octreotide.<Reference refidx="13"/></Para></SummarySection><SummarySection id="_2411"><Title>Sunitinib</Title><Para id="_2412">In an open-label phase II study of sunitinib in adult patients with refractory thymomas, partial responses were observed in 6% of patients, and stable disease was achieved in 75% of patients.<Reference refidx="14"/></Para></SummarySection><Para id="_2309">For more information about the treatment of thymomas, see <SummaryRef href="CDR0000062912" url="/types/thymoma/hp/thymoma-treatment-pdq">Thymoma and Thymic Carcinoma Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_1915"><Title>Treatment Options Under Clinical Evaluation for Childhood Thymoma</Title><Para id="_1916">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="21600006">Carretto E, Inserra A, Ferrari A, et al.: Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis 6: 28, 2011.</Citation><Citation idx="2" PMID="23570972">Allan BJ, Thorson CM, Davis JS, et al.: An analysis of 73 cases of pediatric malignant tumors of the thymus. J Surg Res 184 (1): 397-403, 2013.</Citation><Citation idx="3" PMID="24322668">Fonseca AL, Ozgediz DE, Christison-Lagay ER, et al.: Pediatric thymomas: report of two cases and comprehensive review of the literature. Pediatr Surg Int 30 (3): 275-86, 2014.</Citation><Citation idx="4" PMID="26259494">Stachowicz-Stencel T, Orbach D, Brecht I, et al.: Thymoma and thymic carcinoma in children and adolescents: a report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer 51 (16): 2444-52, 2015.</Citation><Citation idx="5" PMID="10561285" MedlineID="20030014">Thomas CR, Wright CD, Loehrer PJ: Thymoma: state of the art. J Clin Oncol 17 (7): 2280-9, 1999.</Citation><Citation idx="6" PMID="18514130">Tormoehlen LM, Pascuzzi RM: Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 22 (3): 509-26, 2008.</Citation><Citation idx="7" PMID="7792406" MedlineID="95312669">Cowen D, Richaud P, Mornex F, et al.: Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 34 (1): 9-16, 1995.</Citation><Citation idx="8" PMID="19463649">Tomaszek S, Wigle DA, Keshavjee S, et al.: Thymomas: review of current clinical practice. Ann Thorac Surg 87 (6): 1973-80, 2009.</Citation><Citation idx="9">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinoma. Version 2.2018.  Fort Washington, Pa: National Comprehensive Cancer Network, 2018 . <ExternalRef xref="https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf">Available online with free subscription</ExternalRef>. Last accessed June 04, 2019.</Citation><Citation idx="10" PMID="18514127">Casey EM, Kiel PJ, Loehrer PJ: Clinical management of thymoma patients. Hematol Oncol Clin North Am 22 (3): 457-73, 2008.</Citation><Citation idx="11" PMID="8622029" MedlineID="96186207">Giaccone G, Ardizzoni A, Kirkpatrick A, et al.: Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14 (3): 814-20, 1996.</Citation><Citation idx="12" PMID="11391579" MedlineID="21285887">Loehrer PJ, Jiroutek M, Aisner S, et al.: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91 (11): 2010-5, 2001.</Citation><Citation idx="13" PMID="14722038">Loehrer PJ, Wang W, Johnson DH, et al.: Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 22 (2): 293-9, 2004.</Citation><Citation idx="14" PMID="25592632">Thomas A, Rajan A, Berman A, et al.: Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16 (2): 177-86, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_1673"><Title>Childhood Thymic Carcinoma</Title><SummarySection id="_2391"><Title>Incidence and Prognosis</Title><Para id="_1674">The European Cooperative Study Group for Pediatric Rare Tumors identified 20 patients with thymic carcinomas between 2000 and 2012.<Reference refidx="1"/> Complete resection was achieved in only one patient, and five patients survived. The 5-year overall survival rate was 21%.</Para></SummarySection><SummarySection id="_1675"><Title>Treatment of Childhood Thymic Carcinoma</Title><Para id="_1676">Treatment options for childhood thymic carcinoma include the following:</Para><OrderedList id="_2413" Style="Arabic"><ListItem><SummaryRef href="CDR0000799418#_2414" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Surgery</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2416" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2418" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000799418#_2421" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Sunitinib</SummaryRef>.</ListItem></OrderedList><SummarySection id="_2414"><Title>Surgery</Title><Para id="_2415">Surgery is the mainstay of therapy, and an attempt should be made to resect all disease.<Reference refidx="2"/></Para></SummarySection><SummarySection id="_2416"><Title>Radiation therapy</Title><Para id="_2417">Thymic carcinoma is relatively radiosensitive, and radiation therapy is used for patients with unresectable or incompletely resected invasive disease.<Reference refidx="3"/> Radiation dosage recommendations are based on the age of the child and the extent of tumor invasion. Total doses of 45 Gy to 50 Gy may be used for control of clear or close margins, 54 Gy for microscopically positive margins, and at least 60 Gy for patients with bulky residual disease.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_2418"><Title>Chemotherapy</Title><Para id="_2419">Response rates are lower for patients with thymic carcinomas who receive chemotherapy, but 2-year survival rates have been as high as 50%.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_2461">For more information, see the <SummaryRef href="CDR0000799418#_1670" url="/types/thymoma/hp/child-thymoma-treatment-pdq">Treatment of Childhood Thymoma</SummaryRef> section.</Para></SummarySection><SummarySection id="_2421"><Title>Sunitinib</Title><Para id="_2422">In an open-label phase II study of sunitinib in adult patients with refractory thymic carcinomas, partial responses were observed in 26% of patients, and stable disease was achieved in 65% of patients.<Reference refidx="8"/></Para></SummarySection><Para id="_1678">For more information about the treatment of thymic carcinomas in adults, see <SummaryRef href="CDR0000062912" url="/types/thymoma/hp/thymoma-treatment-pdq">Thymoma and Thymic Carcinoma Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_1920"><Title>Treatment Options Under Clinical Evaluation for Childhood Thymic Carcinoma</Title><Para id="_1921">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="26259494">Stachowicz-Stencel T, Orbach D, Brecht I, et al.: Thymoma and thymic carcinoma in children and adolescents: a report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer 51 (16): 2444-52, 2015.</Citation><Citation idx="2" PMID="19463649">Tomaszek S, Wigle DA, Keshavjee S, et al.: Thymomas: review of current clinical practice. Ann Thorac Surg 87 (6): 1973-80, 2009.</Citation><Citation idx="3" PMID="7792406" MedlineID="95312669">Cowen D, Richaud P, Mornex F, et al.: Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 34 (1): 9-16, 1995.</Citation><Citation idx="4">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinoma. Version 2.2018.  Fort Washington, Pa: National Comprehensive Cancer Network, 2018 . <ExternalRef xref="https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf">Available online with free subscription</ExternalRef>. Last accessed June 04, 2019.</Citation><Citation idx="5" PMID="11391579" MedlineID="21285887">Loehrer PJ, Jiroutek M, Aisner S, et al.: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91 (11): 2010-5, 2001.</Citation><Citation idx="6" PMID="1699650" MedlineID="91029060">Carlson RW, Dorfman RF, Sikic BI: Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer 66 (10): 2092-4, 1990.</Citation><Citation idx="7" PMID="20405512">Stachowicz-Stencel T, Bien E, Balcerska A, et al.: Thymic carcinoma in children: a report from the Polish Pediatric Rare Tumors Study. Pediatr Blood Cancer 54 (7): 916-20, 2010.</Citation><Citation idx="8" PMID="25592632">Thomas A, Rajan A, Berman A, et al.: Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16 (2): 177-86, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_2462"><SectMetaData><SectionType>Unusual Cancers Special Considerations</SectionType></SectMetaData><Title>Special Considerations for the Treatment of Children With Cancer</Title>

<Para id="_2462_md_3">Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.<Reference refidx="1"/>    Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills
of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation
to achieve optimal survival and quality of life:</Para>
        <ItemizedList id="_2462_md_4" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Pathologists.</ListItem><ListItem>Pediatric radiation
oncologists.</ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Ophthalmologists.</ListItem><ListItem> Rehabilitation
specialists.</ListItem><ListItem>Pediatric oncology nurses.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child-life professionals.</ListItem><ListItem>Psychologists.</ListItem><ListItem>Nutritionists.</ListItem></ItemizedList>
 <Para id="_2462_md_5">For specific information about supportive care for children and adolescents with cancer, see the summaries on <ExternalRef xref="https://www.cancer.gov/publications/pdq/information-summaries/supportive-care">Supportive and Palliative Care</ExternalRef>.</Para><Para id="_2462_md_6">The American Academy of Pediatrics has outlined guidelines for
pediatric cancer centers and their role in the treatment of children and adolescents
with cancer.<Reference refidx="2"/>  At
these centers, clinical trials are available for most  types of cancer that occur in children and adolescents, and the opportunity
to participate is offered to most patients and their families.  Clinical
trials for children and adolescents diagnosed with cancer are generally
designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis.  Most of the progress in identifying curative
therapies for childhood cancers has been achieved through clinical trials. 
Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_2462_md_7">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.  For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>.</Para>
<Para id="_2462_md_8">Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.<Reference refidx="6"/> The U.S. <ExternalRef xref="https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf">Rare Diseases Act of 2002</ExternalRef> defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.</Para><Para id="_2462_md_9">The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.<Reference refidx="7"/><Reference refidx="8"/> In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:</Para><ItemizedList id="_2462_md_10" Style="bullet"><ListItem>A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included  in the very rare group due to a lack of knowledge and expertise in the management of these tumors.<Reference refidx="9"/></ListItem><ListItem>The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).<Reference refidx="10"/>  These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.<Reference refidx="4"/><Para id="_11"> Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.</Para></ListItem></ItemizedList><Para id="_2462_md_12">These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.</Para><Para id="_2473">Information about these tumors may also be found in sources relevant to
adults with cancer, such as <SummaryRef href="CDR0000062912" url="/types/thymoma/hp/thymoma-treatment-pdq">Thymoma and Thymic Carcinoma Treatment</SummaryRef>.</Para><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2">American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics  134 (2): 410-4, 2014. <ExternalRef xref="https://pediatrics.aappublications.org/content/134/2/410">Also available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="5">Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. 	Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statistics-network/explorer/">Available online</ExternalRef>. Last accessed December 30, 2024.</Citation><Citation idx="6" PMID="24488779">Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr.</Citation><Citation idx="7" PMID="28687376">Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017.</Citation><Citation idx="8" PMID="28542893">DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017.</Citation><Citation idx="9" PMID="30785015">Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019.</Citation><Citation idx="10" PMID="20956621">Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_2304"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (09/12/2024)</Title><Para id="_2305">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_2503">This summary was comprehensively reviewed.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000799418#_AboutThis_1" url="/types/thymoma/hp/child-thymoma-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood thymoma and thymic carcinoma. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Thymoma and Thymic Carcinoma Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Denise Adams, MD (Children's Hospital Boston)</ListItem><ListItem>Karen J. Marcus, MD, FACR (Dana-Farber of Boston Children's Cancer Center and Blood Disorders Harvard Medical School)</ListItem><ListItem>William H. Meyer, MD</ListItem><ListItem>Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)</ListItem><ListItem>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>Alberto S. Pappo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)</ListItem><ListItem>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>Stephen J. Shochat, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Thymoma and Thymic Carcinoma Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/thymoma/hp/child-thymoma-treatment-pdq">https://www.cancer.gov/types/thymoma/hp/child-thymoma-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 31593390]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2019-10-02</DateFirstPublished><DateLastModified>2024-09-12</DateLastModified></Summary>
